Subscribe to Newsletter

The Development of Plasma Amyloid-β Assay and its Significance in Alzheimer’s Disease

The combination of immunoprecipitation (IP) with MALDI-TOF MS resulted in IP-MALDI-MS, an analytical technique that led to the first successful detection of plasma amyloid-β (Aβ) by mass spectrometry. This helped to identify plasma APP669–711/Aβ1–42 ratio, a novel biomarker that correlates with amyloid PET. Samples from Japan and Australia revealed a high degree of concordance between amyloid PET and plasma APP669–711/Aβ1–42 ratio, plasma Aβ1–40/Aβ1–42 ratio, and a combination of both. With advances in disease-modifying drugs, blood-based biomarkers increase in value due to their role in screening subjects and drug effects, and as adjuncts in the diagnosis of AD.

>> Download App Note as a PDF

Find out more on Shimadzu's website here

>Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine